Intranasal zolmitriptan is effective and well tolerated in acute cluster headache

Completed

• Conditions: Headache; Cluster headache; Signs and Symptoms

• Registration Number: ISRCTN27362692
• Lead Sponsor: AstraZeneca (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02-23
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Cluster headache with attacks longer than 45 minutes.

Exclusion Criteria

Contraindications to zolmitriptan in participating countries.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of patients who have taken active drug with headache relief at 30 minutes.

Secondary Outcome Measures

Name	Time	Method
Pain free at 30 minutes.